REVOLUTION MEDICINES INC

Phase 3 data show daraxonrasib extends survival and quality‑of‑life for metastatic pancreatic cancer, offering a new oral RAS inhibitor with fewer side‑effects than chemo.

Revolution Medicines’ inclusion in GraniteShares’ leveraged ETF signals growing investor appetite for high‑growth biotech. Explore how RM’s clinical milestones and regulatory designations could shape future stock volatility and patient outcomes.

Revolution Medicines launches an expanded access program for daraxonrasib, a KRASG12D‑targeted agent boosting survival in pancreatic cancer patients with limited options.

Revolution Medicines to unveil Phase‑1 data for its KRAS G12D inhibitor, zoldonrasib, at AACR 2026, promising a 50%+ ORR and 1‑year PFS in heavily pre‑treated NSCLC patients.

Revolution Medicines raises $2.2 billion via equity and convertible notes, funding RAS‑targeted oncology R&D and potential commercialization while maintaining investor confidence.